Overview

Ametris partnered with Johnson & Johnson Innovative Medicine to improve wearable adherence in the global Phase 3 LIBERTAS trial for a metastatic castration-sensitive prostate cancer (mCSPC) therapy. In this study, actigraphy devices were used for more than 12 months to continuously measure sleep quality and physical activity as objective proxies for hot flash burden.  

By implementing a real-time, data-driven site intervention workflow, the study achieved nearly 90% adherence and sustained high daily wear time, as reported in recently published results. These improvements reduced missing data, lowered endpoint variability, and helped avoid costly study delays, demonstrating the value of active adherence management in long duration oncology trials.

Read the full case study to learn more about:

• How real-time, data-driven intervention workflows can improve adherence and data completeness in long-duration studies
• Achieving sustained, long-term wearable adherence in older, clinically complex oncology populations
• Reducing missing data and variability to more reliable endpoint evaluation and overall study success
  
  

Related Resources:

• Access the on-demand webinar on DHT Adherence Insights and Good Practice for Clinical Development
• Choose the right level of support for Adherence Monitoring Solutions.
• Review our recommendations when it comes to enhancing oncology-focused research with wearable DHTs in our Oncology Digital Endpoint Guide.